The clinical application of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9 inhibitor) has opened a new gate for lipid‐lowering therapy, but atherosclerosis is a chronic inflammatory process, and lipid‐lowering drugs cannot effectively reduce the inflammatory response. The gene discussed is PCSK9; the disease is atherosclerosis.